Milestone Pharmaceuticals (NASDAQ:MIST - Get Free Report) released its earnings results on Thursday. The company reported ($0.19) EPS for the quarter, missing the consensus estimate of ($0.15) by ($0.04), Zacks reports.
Milestone Pharmaceuticals Stock Performance
NASDAQ:MIST opened at $1.93 on Thursday. The company has a market cap of $102.92 million, a price-to-earnings ratio of -2.38 and a beta of 1.83. Milestone Pharmaceuticals has a 1 year low of $1.12 and a 1 year high of $2.75. The stock's 50 day simple moving average is $2.02 and its two-hundred day simple moving average is $1.79. The company has a debt-to-equity ratio of 2.18, a current ratio of 15.40 and a quick ratio of 15.40.
Analyst Upgrades and Downgrades
Separately, HC Wainwright reiterated a "buy" rating and issued a $25.00 price target on shares of Milestone Pharmaceuticals in a research note on Friday, February 28th.
Check Out Our Latest Stock Report on Milestone Pharmaceuticals
About Milestone Pharmaceuticals
(
Get Free Report)
Milestone Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization of cardiovascular medicines. The company's lead product candidate is etripamil, a novel and potent calcium channel blocker, which is in Phase III clinical trial for the treatment of paroxysmal supraventricular tachycardia in the United States and Canada; and Phase II clinical trial for the treatment of atrial fibrillation and rapid ventricular rate.
See Also
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Milestone Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Milestone Pharmaceuticals wasn't on the list.
While Milestone Pharmaceuticals currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
